Table 2.
Safety analysis of HTX-019
| Number of patients | |
|---|---|
| Adverse events | 0 |
| Discontinuing HTX-019 | 0 |
| Switched from HTX-019 to alternate NK-1 receptor antagonist | 0 |
NK-1 neurokinin 1
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.